rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MIRM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Mirum Pharmaceuticals CFO Eric Bjerkholt sells $978,092 shares
      Nov 16Investing.comMIRM
      Mirum Pharmaceuticals director Laura Brege sells $1.33M in shares
      Nov 14Investing.comMIRM
      Mirum Pharmaceuticals at Stifel 2026 Healthcare Conference: growth broadens
      Nov 11Investing.comMIRMSF
      Mirum’s brelovitug meets primary endpoint in second phase 3 trial
      Nov 10Investing.comMIRM
      GeneDx and Mirum to provide genetic tests for cholestasis, cataracts or PBD-ZSD
      Nov 6Yahoo FinanceMIRMWGS
      GeneDx partners with Mirum for free genetic testing program
      Nov 5Investing.comMIRMWGS
      GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
      Nov 5Yahoo FinanceMIRMWGS
      Why Mirum Pharmaceuticals (MIRM) Is Up 11.4% And What's Next After Earnings Beat

      Mirum Pharmaceuticals reported Q3 2026 net product sales of about US$186 million, lifted its full year sales guidance, and highlighted strong demand for LIVMARLI, bile acid medicines, and the initial U.S. launch of ATEBRIOZ following FDA approval for fibrodysplasia ossificans progressiva. Alongside the commercial update, Mirum outlined progress across rare disease programs, including ATEBRIOZ expansion in younger FOP patients and continued work on maralixibat and other Progressive Familial...

      Nov 5Yahoo FinanceMIRM
      Mirum Pharmaceuticals CEO Peetz sells $1.8M in stock
      Nov 5Investing.comMIRM
      H.C. Wainwright raises Mirum Pharmaceuticals price target to $202
      Nov 4Investing.comMIRM
      Raymond James raises Mirum Pharmaceuticals price target on commercial strength
      Nov 4Investing.comMIRM
      Citizens raises Mirum Pharmaceuticals price target on pipeline progress
      Nov 4Investing.comMIRM
      Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance, $500 ...
      Nov 4Yahoo FinanceMIRM
      Mirum Pharmaceuticals Q3 Earnings Call Highlights
      Nov 4Yahoo FinanceMIRM
      Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript
      Nov 3BenzingaMIRM
      Mirum Pharmaceuticals earnings missed by $0.38, revenue topped estimates
      Nov 3Investing.comMIRM
      Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
      Nov 3Yahoo FinanceMIRM
      Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
      Nov 3Yahoo FinanceMIRM
      Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 3Yahoo FinanceMIRM
      Mirum Pharmaceuticals earnings: Can pipeline wins lift stock?
      Nov 3Investing.comMIRM
      Mirum Pharmaceuticals (MIRM) Stock Trades Near Fair Value As Pediatric FOP Study Progresses
      Oct 28Yahoo FinanceMIRM
      Mirum Pharmaceuticals (MIRM) Could Be 44% Undervalued On Pediatric FOP Trial Data
      Oct 28Yahoo FinanceMIRM
      Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
      Oct 27Yahoo FinanceMIRM
      Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

      Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 27Yahoo FinanceMIRM
      Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
      Oct 26Yahoo FinanceMIRM
      Mirum reports positive trial results for FOP drug in children
      Oct 26Investing.comMIRM
      Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      FOSTER CITY, Calif., October 21, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

      Oct 21Yahoo FinanceMIRM
      Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 15Yahoo FinanceMIRM
      Stifel raises Mirum Pharmaceuticals stock price target on approvals
      Oct 15Investing.comMIRM
      Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
      Oct 13Yahoo FinanceMIRM
      Morgan Stanley raises Mirum Pharmaceuticals price target on EXPAND study data
      Oct 13Investing.comMIRM
      Raymond James reiterates Strong Buy on Mirum stock after trial data
      Oct 12Investing.comMIRMRJF
      Mirum tees up Livmarli label expansion on Phase III liver disease study success
      Oct 12Yahoo FinanceMIRM
      Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
      Oct 12Yahoo FinanceMIRM
      Baird reiterates Mirum Pharmaceuticals stock rating on trial success
      Oct 12Investing.comMIRM
      TD Cowen reiterates Mirum Pharmaceuticals stock Buy rating at $140
      Oct 12Investing.comMIRM
      Stifel reiterates Buy on Mirum Pharmaceuticals stock, $136 target
      Oct 12Investing.comMIRMSF
      RBC Capital reiterates Mirum Pharmaceuticals stock rating on trial data
      Oct 12Investing.comMIRM
      Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia - Slideshow (NASDAQ:MIRM) 2026-10-12

      2026-10-12. The following slide deck was published by Mirum Pharmaceuticals, Inc.

      Oct 12Seeking AlphaMIRM
      Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases

      Mirum Pharma’s phase 3 EXPAND trial shows Livmarli eased cholestatic pruritus and cut bile acids. Read more here.

      Oct 12Seeking AlphaMIRM
      Why Is Mirum Pharmaceuticals Stock Gaining Monday? - Mirum Pharmaceuticals (NASDAQ:MIRM)

      Mirum stock surges after LIVMARLI wins Phase 3 trial, showing significant itch and bile acid reduction in biliary atresia patients.

      Oct 12BenzingaMIRM
      Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease
      Oct 12Investing.comMIRM
      Mirum Pharmaceuticals Says Livmarli Meets Primary Endpoint in Phase 3 Liver Disease Trial
      Oct 12Yahoo FinanceMIRM
      Mirum’s maralixibat meets primary endpoint in liver disease trial
      Oct 12Investing.comMIRM
      Mirum Pharmaceuticals to report Livmarli trial results Monday (MIRM:NASDAQ)

      Mirum Pharma (MIRM) reports Phase 3 EXPAND LIVMARLI topline results Oct 12.

      Oct 11Seeking AlphaMIRM
      Mirum Pharmaceuticals to share phase 3 LIVMARLI study results
      Oct 11Investing.comMIRM
      Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP)

      Detailed price information for Helus Pharma Inc (HELP-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailCNTBMIRM
      RBC Raises Price Target on Mirum Pharmaceuticals to $155 From $135, Keeps Outperform Rating
      Oct 8Yahoo FinanceMIRM
      Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study

      Mirum Pharmaceuticals (NASDAQ:MIRM) reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile. The company

      Oct 2Yahoo FinanceMIRM
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Kodiak Sciences Inc (KOD-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailMIRM

      This is the newest page. Registered accounts read further back.